Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI)

drug protocol number
D5160C00022
drug sponsor
AstraZeneca
drug study
Osimertinib (AZD9291)
drug trial site
KFSH
drug status
Completed
drug phase